FDA extends interim deal but issues dog CryoLife
This article was originally published in Clinica
Things do not seem to be getting any worse for CryoLife, but they are not getting better very quickly either. The Atlanta, Georgia firm is still striving to shake free of the contamination issues that had such a negative effect on it for much of last year. Meanwhile, it faces ongoing compliance problems with its reporting procedures for adverse reactions.
You may also be interested in...
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.